Jennifer Epler
Publications by Year
Research Areas
Colorectal Cancer Treatments and Studies, Cancer therapeutics and mechanisms, DNA Repair Mechanisms, Lung Cancer Treatments and Mutations, Melanoma and MAPK Pathways
Most-Cited Works
- → Design of Selective PAK1 Inhibitor G-5555: Improving Properties by Employing an Unorthodox Low-p K a Polar Moiety(2015)83 cited
- → Chemically Diverse Group I p21-Activated Kinase (PAK) Inhibitors Impart Acute Cardiovascular Toxicity with a Narrow Therapeutic Window(2016)76 cited
- → Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors(2018)76 cited
- → Recognition of Breast Cancer Cells by CD8+ Cytotoxic T-Cell Clones Specific for NY-BR-1(2006)53 cited
- → Discovery and Biological Profiling of Potent and Selective mTOR Inhibitor GDC-0349(2012)46 cited
- → Regulation of β1 Integrin-Mediated Adhesion by T Cell Receptor Signaling Involves ZAP-70 but Differs from Signaling Events That Regulate Transcriptional Activity(2000)42 cited
- → Combination Drug Scheduling Defines a “Window of Opportunity” for Chemopotentiation of Gemcitabine by an Orally Bioavailable, Selective ChK1 Inhibitor, GNE-900(2013)36 cited
- → Pyrimidoaminotropanes as Potent, Selective, and Efficacious Small Molecule Kinase Inhibitors of the Mammalian Target of Rapamycin (mTOR)(2013)31 cited
- → Potent, Selective, and Orally Bioavailable Inhibitors of the Mammalian Target of Rapamycin Kinase Domain Exhibiting Single Agent Antiproliferative Activity(2012)30 cited
- → Potent, Selective, and Orally Bioavailable Inhibitors of Mammalian Target of Rapamycin (mTOR) Kinase Based on a Quaternary Substituted Dihydrofuropyrimidine(2011)24 cited